On June 29-30, the 9th China Biomedical Innovation and Cooperation Conference and the Hua Yi Bang 2023 China Biomedical Industry Value List Award Ceremony were grandly held in Suzhou. NeuroXess successfully made it to the "Top 10 Most Growth-Oriented Biotechnology Companies" in the 2023 China Biomedical Industry Value List with its unique biotechnology. Professor Tao Hu, founder and chief scientist of NeuroXess, attended the conference and went on stage to accept the honor.
It is reported that the list was selected by Huayi Research Institute, which judged from multiple dimensions such as competitive elements, commercialization elements, value elements, strategic elements, product elements, and team elements. After an in-depth evaluation of the industry, sector, and enterprises, it identified truly innovative companies in the biopharmaceutical field with industry influence and growth potential.
NeuroXess's inclusion in this ranking is due to its long-term self-developed technological achievements and representative industry status in the field of invasive flexible brain-computer interfaces. Currently, NeuroXess has successfully implemented several core technology achievements, including flexible electrodes, biomaterials, high-throughput neural signal acquisition systems, surgical robots, and a digital brain algorithm cloud platform, all of which have applied for patent protection. In addition, NeuroXess has built comprehensive capabilities from research to commercialization, creating an end-to-end complete solution.
Tao Hu stated that the successful inclusion in the "TOP10 Most Growth-Oriented Biotechnology Enterprises" list is a comprehensive affirmation and recognition by the industry and society of NeuroXess' R&D innovation capabilities, corporate influence, business philosophy, and development strategy. In the future, NeuroXess will remain true to its original mission and continue to move forward. By providing innovative, effective, and feasible solutions to the scientific research market and the medical market, it aims to contribute to academia, the medical community, and even the entire brain science industry.